(Q35840390)

10 August 2017

1 reference

title

Estrogens and epithelial ovarian cancer (English)

1 reference

10 August 2017

1 reference

1 reference

3

Pascal Pujol

1 reference

10 August 2017

Séverine Cunat

1

1 reference

PubMed ID

15262115

10 August 2017

Pascale Hoffmann

series ordinal

2

1 reference

PubMed ID

15262115

10 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

94

1 reference

10 August 2017

25-32

1 reference

10 August 2017

1

1 reference

10 August 2017

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Molecular approaches to diagnosis and management of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Ovarian surface epithelium: biology, endocrinology, and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Risk factors for ovarian cancer: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Hormone replacement therapy and risk of epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen replacement therapy and ovarian cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen replacement therapy and risk of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Long-term surveillance of mortality and cancer incidence in women receiving hormone replacemen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Risk of cancer in women receiving hormone replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen replacement therapy and fatal ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Menopausal hormone replacement therapy and risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

inferred from DOI database lookup

7 January 2021

based on heuristic

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Endocrine Factors in Common Epithelial Ovarian Cancer*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

ER beta: identification and characterization of a novel human estrogen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Absence of estrogen receptor-beta expression in metastatic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Loss of Estrogen Receptor Expression in Malignant Human Prostate Cells in Primary Cultures and in Prostate Cancer Tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen receptor β expression in human prostate tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

ER beta inhibits proliferation and invasion of breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen action in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Expression of the pNR-2/pS2 protein in diverse human epithelial tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

c-myc amplification in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

C-myc oncogene product P62c-myc in ovarian mucinous neoplasms: immunohistochemical study correlated with malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

c-erbB-2 oncogene expression in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Clinical significance of cathepsin D in primary ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Kallikrein 4 (KLK4), A New Member of the Human Kallikrein Gene Family Is Up-Regulated By Estrogen and Progesterone in the Human Endometrial Cancer Cell Line, KLE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

BRCA1 Inhibition of Estrogen Receptor Signaling in Transfected Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Endocrine characterization of a human ovarian carcinoma (BG-1) established in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Properties and regulation of 17 beta-hydroxysteroid oxidoreductase of OVCAR-3, CAOV-3, and A431 cells: effects of epidermal growth factor, estradiol, and progesterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Local aromatase activity in human breast tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

Anti-tumor effects of letrozole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.026

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2004.03.026

1 reference

10 August 2017

1 reference

PubMed ID

15262115